Phase Ib Study of Drozitumab Combined With First-Line mFOLFOX6 Plus Bevacizumab in Patients with Metastatic Colorectal Cancer-Reference-Cited by-同舟云学术

Phase Ib Study of Drozitumab Combined With First-Line mFOLFOX6 Plus Bevacizumab in Patients with Metastatic Colorectal Cancer

Published:2012-10-12 Issue:10 Volume:30 Page:727-731
ISSN:0735-7907
Container-title:Cancer Investigation
language:en
Short-container-title:Cancer Investigation

Author:

Rocha Lima Caio M.,Bayraktar Soley,Flores Aurea M.,MacIntyre Jessica,Montero Alberto,Baranda Joaquina C.,Wallmark John,Portera Chia,Raja Rajiv,Stern Howard,Royer-Joo Stephanie,Amler Lukas C.

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,General Medicine

Link

http://www.tandfonline.com/doi/pdf/10.3109/07357907.2012.732163

Reference10 articles.

1. Cancer Facts and Figures. 2012. Available at: http://www.cancer. org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-031941.pdf

2. Innovations in Chemotherapy for Metastatic Colorectal Cancer: An Update of Recent Clinical Trials

3. First-line chemotherapy in metastatic colorectal cancer: new approaches and therapeutic algorithms. Always hit hard first?

4. Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study

5. Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Phage display for discovery of anticancer antibodies;New Biotechnology;2024-11

2. TRIAL-based combination therapies in cancers;International Immunopharmacology;2024-09

3. Acquired Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) Resistance of Human Colorectal Cancer Cells Is Linked to Histone Acetylation and Is Synergistically Ameliorated by Combination with HDAC Inhibitors;Digestive Diseases and Sciences;2024-08-01

4. Selectively targeting myeloid-derived suppressor cells through TRAIL receptor 2 to enhance the efficacy of CAR T cell therapy for treatment of breast cancer;Journal for ImmunoTherapy of Cancer;2021-11

5. Bone Marrow Mesenchymal Stromal Cell-mediated Resistance in Multiple Myeloma Against NK Cells can be Overcome by Introduction of CD38-CAR or TRAIL-variant;HemaSphere;2021-04-21